Dova Pharmaceuticals Email Format

BiotechnologyNorth Carolina, United States51-200 Employees

Dova Pharmaceuticals is a growing specialty pharmaceutical company focused on developing medicines for patients with rare diseases. Based in Durham, North Carolina, it seeks to build a portfolio of differentiated therapies intended to improve health and well-being in this community. Its lead product, Doptelet (avatrombopag), was launched in 2018 to treat thrombocytopenia in adults with chronic liver disease undergoing a procedure. In 2019, the FDA approved a second indication and the European Union granted approval in the same year.

Dova operates within the biotechnology research sector and is a wholly owned subsidiary of Swedish Orphan Biovitrum AB (Sobi). In 2019, the company announced an agreement and plan of merger with Sobi, signaling a closer corporate relationship. The information depicts a mid-sized organization focused on expanding access to therapies for rare diseases in the United States and Europe.

Sign up for free to view info

Company overview Employee directory